Business
Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX(TM) (ozenoxacin cream 1%)
Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX™ (ozenoxacin cream...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCipher Pharmaceuticals Receives Health Canada Approval of OZANEX™ (ozenoxacin cream 1%)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen4{\nBORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prngen3{\nBORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbtb0{\nBORDER-BOTTOM:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMISSISSAUGA, ON, May 8, 2017\n\n\n\nMISSISSAUGA, ON, May 8, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients aged 2 months and older1. \n\n\"The approval of OZANEX offers a new and effective treatment option for young children suffering with one of the most common and contagious bacterial skin infections,\" said Dr. Ian Landells, a Pediatric Dermatologist from St. John's, Newfoundland. \"It's the first bacteriocidal topical antibiotic and has been shown to be effective against resistant bacteria such as MRSA.\"\n\nOZANEX, which belongs to a new generation of non-fluorinated quinolones, offers a short 5-day BID dosing regimen and has shown bacteriological eradication as early as day 3 of treatment.\n\nThe Health Canada approval was based on two multicentre, randomized, placebo controlled Phase III studies involving 875 adult and pediatric subjects with impetigo. The results of the clinical program confirmed the efficacy of OZANEX cream on both clinical and bacteriologic...